RECRUITINGOBSERVATIONAL

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

About This Trial

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age from 16 years and older. 2. Gender: both sexes are included. 3. Clinical Diagnosis of MG with supporting evidence as: 1. unequivocal clinical response to pyridostigmine 2. decrement \>10% in repetitive nerve stimulations study (RNS). 4. Willingness to sample collection, imaging study and other disease-related examinations and assessments. Who Should NOT Join This Trial: 1. Age younger than 16 years. 2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue. 3. Severe systemic illness affecting life-expectancy. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Age from 16 years and older. 2. Gender: both sexes are included. 3. Clinical Diagnosis of MG with supporting evidence as: 1. unequivocal clinical response to pyridostigmine 2. decrement \>10% in repetitive nerve stimulations study (RNS). 4. Willingness to sample collection, imaging study and other disease-related examinations and assessments. Exclusion Criteria: 1. Age younger than 16 years. 2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue. 3. Severe systemic illness affecting life-expectancy.